Replimune (REPL) EPS (Basic) (2017 - 2026)

Replimune (REPL) posted EPS (Basic) of -$0.79 for Q1 2026, down 2.54% sequentially from -$0.77 in Q4 2025, and up 14.26% YoY from -$0.69 in Q1 2025.

Analysis

Replimune (REPL) EPS (Basic) (2017 - 2026) Analysis & Trends

Replimune has reported EPS (Basic) for 10 years, with the latest figure at -$0.79 in Q1 2026.

Quarterly EPS (Basic) rose 14.26% year-over-year to -$0.79 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.38 (down 10.21% YoY) and the FY2026 annual result came in at -$3.38, down 10.21% from the prior year.
EPS (Basic) declined to -$0.79 in Q1 2026 per REPL's latest filing, from -$0.77 in the prior quarter.
Over five years, EPS (Basic) peaked at -$0.61 in Q1 2022 and troughed at -$0.95 in Q2 2025.
A 5-year average of -$0.8 and a median of -$0.79 in 2022 frame the typical range for EPS (Basic).
The sharpest annual moves came in 2022 and 2024: EPS (Basic) plunged 48.14% in 2022, then increased 25.12% in 2024.
Over 5 years, EPS (Basic) stood at -$0.69 in 2022, then declined by 11.81% to -$0.77 in 2023, then dropped by 3.58% to -$0.79 in 2024, then advanced by 3.16% to -$0.77 in 2025, then declined by 2.54% to -$0.79 in 2026.
According to Business Quant data, EPS (Basic) over the past three periods registered -$0.79, -$0.77, and -$0.9 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EPS (Basic) (Qtr)
1	Vertex Pharmaceuticals	139.76 Bn	131.91 Bn	2.84 Bn	4.34
2	Regeneron Pharmaceuticals	85.72 Bn	77.72 Bn	3.93 Bn	12.62
3	Argenx Se	63.56 Bn	58.38 Bn	1.37 Bn	7.70
4	Moderna	57.87 Bn	52.73 Bn	52.00 Mn	-1.96
5	Revolution Medicines	44.06 Bn	44.06 Bn	-	-3.06
6	BeOne Medicines	40.08 Bn	34.98 Bn	1.53 Bn	2.12
7	Alnylam Pharmaceuticals	35.50 Bn	32.20 Bn	992.69 Mn	1.23
8	Royalty Pharma	28.54 Bn	27.70 Bn	-	0.18
9	Insmed	27.49 Bn	26.33 Bn	358.27 Mn	-0.06
10	Replimune	1.46 Bn	1.46 Bn	-	-0.72

Historic Data

Download Data